Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 2,006 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Discrete Clear all

Conditions: ICU Acquired Weakness
Interventions: Clinical Electrical Stimulator; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cellulite
Interventions: cryolipolysis, Subcision, Control; Device · Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Post-traumatic Headache, Mild Traumatic Brain Injury
Interventions: Acupuncture; Procedure
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Interaction Drug Food
Interventions: Midazolam HCl, Dextromethorphan HBr, Kratom; Drug · Dietary Supplement
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Pancreatic Cancer
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Cincinnati; Other
Eligibility: 19 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Osteoporosis
Interventions: Standard Clinical Practice Regimen, Experimental Cyclic Regimen; Drug
Lead sponsor: Health Research, Inc.; Other
Eligibility: 45 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: West Haverstraw, New York

Conditions: Substance-Related Disorders
Interventions: Paired, Stimulant or sedative, Placebo; Behavioral · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cognitive Control, Executive Function
Interventions: Theta-gamma tACS, Delta-beta tACS, Sham tACS; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions: Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: RSV Infection, QTc Interval
Interventions: zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo, moxifloxacin; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Lenexa, Kansas • San Antonio, Texas

Conditions: Healthy
Interventions: HIP2B, Placebo; Drug
Lead sponsor: CureDM; Industry
Eligibility: 19 Years to 45 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Eating Disorders
Interventions: Positron Emission Tomography (PET) using [11C]raclopride, Methylphenidate, Magnetic Resonance Imaging (MRI) scan; Radiation · Drug · Procedure
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke
Interventions: One group received the psychosocial intervention, while the other group engaged in IADL interventions.; Behavioral
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Unilateral Carpal Tunnel Syndrome
Interventions: StimRouter System; Device
Lead sponsor: Bioness Inc; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Healthy
Interventions: Lyophilized Plasma, Fresh Frozen Plasma; Biological · Other
Lead sponsor: HemCon Medical Technologies, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers
Interventions: TPIP F2, TPIP F3; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Migraine
Interventions: Botulinum toxin type A, Placebo; Biological · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more

Conditions: Prostate Adenocarcinoma, Prostate Carcinoma
Interventions: Magnetic Resonance Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease
Interventions: Verinurad, Allopurinol, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV Infections, Substance Use Disorders, Mental Health Disorder, Addiction, Opioid Use, Drug Use
Interventions: Collaborative Care Model; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Safety, Pharmacokinetics, Healthy Subjects
Interventions: Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg), Anifrolumab placebo SC injection (300mg), Anifrolumab placebo IV infusion (300mg), Anifrolumab placebo SC infusion (600mg); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vestibulodynia
Interventions: Fractional CO2 Laser Treatment, Sham Laser Treatment; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Ductal Carcinoma in Situ - Category, Breast Cancer, Prophylactic Mastectomy
Interventions: Inframammary Fold Incision or Lateral Radial Incision, Lateral Radial Incision, Inframammary Fold Incision, Laser-assisted fluorescence angiography, Indocyanine Green; Procedure · Device · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
Interventions: [18F]FTP PET/CT; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Diagnosing Intensive Care Unit (ICU) Acquired Weakness

Cryolipolysis and Subcision for Treatment of Cellulite

Acupuncture in Traumatic Brain Injury

Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product

Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body

The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

Interactions Between Drug Effects and Environments II

Effect of Cross Frequency tACS on Cognitive Control

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

A Study of Subcutaneous Doses of HIP2B in Healthy Male Subjects

Changes in Dopamine Levels Before and After Weight Restoration in People With Anorexia Nervosa

Occupational Therapy Instructmental Activities of Daily Living and Psychosocial Modules Program for Stroke Survivors

Acute Human Study: StimRouter for Peripheral Nerve Stimulation of Discrete Peripheral Nerves

The Safety of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Healthy Volunteers

A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care

A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

Randomized CO2 vs Sham Laser Treatment of Provoked Vestibulodynia

Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT